SELLAS Life Sciences Group, Inc. (SLS)
CIK 1390478 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 201.9M shares as of Aug 10, 2026 (10-Q).⊙
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| September2025 Inducement | 19.7M | $1.88 | — | — |
| March2024 Registered Direct Offering | 4.7M | $1.41 | — | — |
| October2025 Inducement | 4.1M | $2 | — | — |
| Other Warrant Issues | 985,000 | $1.73 | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 11, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 9.7M underlying shares, as reported Jun 30, 2026 (10-Q).
Reported exercise price: $1.7 (aggregate figure as tagged; individual tranches vary).
Balance-sheet fair value of warrants: $11.9M as of Jun 30, 2011.
Down-round (price protection) accounting has been tagged in this filer’s XBRL: some instrument carries repricing protection. Which tranche requires reading the exhibits.
Rough fully diluted estimate: 211.7M = 201.9M O/S + 9.7M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
No convertible-note facts tagged in the 10-Q filed Aug 11, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 201.9M | Aug 10, 2026 |
| + September2025 Inducement (if exercised) | 19.7M | Dec 31, 2025 |
| + March2024 Registered Direct Offering (if exercised) | 4.7M | Jun 30, 2026 |
| + October2025 Inducement (if exercised) | 4.1M | Jun 30, 2026 |
| + Other Warrant Issues (if exercised) | 985,000 | Jun 30, 2026 |
| Fully diluted estimate | 231.3M | +14.6% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $186.7Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 1 executed · 1 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full SLS workspace